Inside the male body lies a small but mighty gland called the prostate, and unfortunately, it’s not immune to trouble. Prostate cancer can be a sneaky villain, lurking in the shadows without any symptoms.
But fear not!
Early detection is the key to defeating this foe, especially regarding aggressive prostate cancer. By catching it early, we can unleash a powerful arsenal of treatments and give ourselves the best chance at a triumphant victory over this formidable opponent. So gentlemen, let’s suit up, get regular check-ups, and keep our superpowers intact!
What Tests Can Identify Prostate Cancers?
Let’s roll out the red carpet for genomic testing and explore the prostate cancer identification heroes lineup!
- Prostate-Specific Antigen Testing:
First up, we have the PSA test, a popular choice. It measures the levels of a protein called prostate-specific antigen in the blood, raising a flag if something seems amiss. However, while helpful, it may provide a partial picture.
- Biopsy:
Next, we have the biopsy, a more precise contender. It involves collecting tissue samples from the prostate for examination under a microscope. This method allows for a closer look at suspicious areas and can detect cancerous cells more accurately.
- Genomic Testing:
But hold on tight because here comes the show’s real star: genomic testing for prostate cancer! Armed with the power of analysing the genetic makeup of prostate cancer cells, this method takes identification to the next level. It reveals the specific mutations and alterations in the tumour’s DNA, unlocking insights about its behaviour and potential treatment options.
What is a Genomic Test for Prostate Cancer?
This cutting-edge technique dives deep into the genetic blueprint of prostate cancer cells, uncovering their secrets and shedding light on the best prostate cancer treatment strategies.
- Genomic testing dives into the DNA of tumour cells, like a detective investigating clues.
- It identifies specific genetic alterations and mutations that are responsible for driving the growth of cancer.
- By decoding this molecular fingerprint, doctors gain invaluable insights into how cancer behaves, like uncovering its secret playbook.
- With this knowledge, personalised treatment plans can be created, like a custom-made suit, targeting the tumour’s weaknesses with laser-like precision.
A Genomic Prostate Score (GPS) is generated through genomic testing, ranging from 0 to 100, aiding medical teams in gauging the level of risk and making informed treatment decisions. A higher GPS suggests an increased likelihood of aggressive cancer tumours in the future.
The Oncotype DX test examines 17 genes widely used in Australia. In contrast, Decipher and Prolaris tests provide a 10-year risk assessment for prostate cancer. These tests empower clinicians with valuable information to guide personalised treatment approaches.
Is a Genomic Test Better at Finding Aggressive Prostate Cancer?
Genomic testing goes beyond traditional methods by analysing tumour cell genetic alterations and mutations. This allows for a deeper understanding of aggressive prostate cancer, enabling personalised treatment plans targeting unique characteristics.
In a groundbreaking study, genomic testing for prostate cancer has proven to outshine conventional tests in identifying aggressive forms of the disease. This advanced test, Decipher, evaluates the activity of 22 specific genes, accurately predicting the risk of tumour spread or metastasis. The study highlights the importance of customising cancer treatment according to the cancer’s level of aggression.
Unlike traditional tests that rely on clinical markers such as Gleason score and PSA level, Decipher provides a more comprehensive and precise assessment. Intriguingly, the study revealed that the Decipher test identified high-risk cancer in certain individuals, even when conventional tests indicated lower risk.
By incorporating genomic testing, healthcare professionals can offer personalised treatment plans, ensuring that high-risk tumours receive adequate intervention while sparing lower-risk tumours unnecessary treatment.
Although the Decipher test has been available for years, broader recommendations from medical groups for its use in newly diagnosed, localised prostate cancer cases are yet to be established.
Benefits Of Genomic Prostate Scoring In Treating Cancer
- GPS enables a more accurate assessment of the cancer’s aggressiveness, allowing for tailored treatment decisions.
- GPS helps identify low-risk cases that can be managed with non-invasive approaches like Active Surveillance, avoiding unnecessary interventions.
- GPS prompts early consideration of definitive treatments for high-risk cases, ensuring timely and effective management.
- Genomic testing improves treatment outcomes by reducing guesswork and providing a clearer understanding of cancer’s behaviour, leading to more successful and targeted interventions.
How to Prepare For Genomic Testing?
- Patients referred for genomic testing undergo a biopsy to collect a tissue sample.
- The biopsy procedure is quick, simple, and requires minimal preparation.
- The procedure is usually completed in just a few minutes.
- Your GP or urologist will explain the testing process and necessary preparations.
- Combining biopsy and genomic testing helps determine the risk of cancer progression.
- The procedure, taking just a few minutes, can significantly affect treatment options, potentially avoiding invasive surgeries and enabling non-invasive management approaches.
Conclusion
Genomic testing proves to be a game-changer in identifying aggressive prostate cancer. Analysing the genetic makeup of tumour cells provides crucial insights into cancer’s behaviour and helps tailor personalised treatment plans.
With its ability to predict risk and guide treatment decisions, genomic testing offers a more practical approach to managing this complex disease, ultimately improving patient outcomes and empowering healthcare professionals in the fight against prostate cancer.
